Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
ADC Drug Map | Antibody-drug Conjugates Database
View through CrossRef
Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker. ADCs have become a powerful class of therapeutic agents in oncology and hematology. Using the latest published peer-reviewed data, the editors of ADC Review | Journal of antibody-drug Conjugates set out to develop the first comprehensive database of therapeutic ADCs in pre-clinical and clinical development as well as providing updates about studies and regulator-approved ADCs. Using multiple sources, the database will be frequently updated with the latest available data.
Title: ADC Drug Map | Antibody-drug Conjugates Database
Description:
Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.
ADCs have become a powerful class of therapeutic agents in oncology and hematology.
Using the latest published peer-reviewed data, the editors of ADC Review | Journal of antibody-drug Conjugates set out to develop the first comprehensive database of therapeutic ADCs in pre-clinical and clinical development as well as providing updates about studies and regulator-approved ADCs.
Using multiple sources, the database will be frequently updated with the latest available data.
Related Results
Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Abstract
Antibody drug conjugates (ADCs) are an effective class of cancer therapeutics which have become more prominent after eight FDA approvals in the past three y...
Abstract 210: Novel antibody drug conjugate to inhibit mesothelioma tumor growth
Abstract 210: Novel antibody drug conjugate to inhibit mesothelioma tumor growth
Abstract
Mesothelioma is an aggressive but rare form of cancer with a poor prognosis. 1-year survival is ~40% and 5-year survival remains in single digits. Treatment...
Characteristics and Role of Apparent Diffusion Coefficient (ADC) Value in Musculoskeletal Soft Tissue Tumor
Characteristics and Role of Apparent Diffusion Coefficient (ADC) Value in Musculoskeletal Soft Tissue Tumor
Introduction: Musculoskeletal soft tissue tumors (STTs) consist of a group of malignant and benign tumors that present challenges in diagnosis and therapy. Adding diffusion-weighte...
Technical note: Temperature and concentration dependence of water diffusion in polyvinylpyrrolidone solutions
Technical note: Temperature and concentration dependence of water diffusion in polyvinylpyrrolidone solutions
AbstractObjectiveThe goal of this work is to provide temperature and concentration calibration of water diffusivity in polyvinylpyrrolidone (PVP) solutions used in phantoms to asse...
Procedure for Western blot v1
Procedure for Western blot v1
Goal: This document has the objective of standardizing the protocol for Western blot. This technique allows the detection of specific proteins separated on polyacrylamide gel and t...
The Target Atlas for Antibody-Drug Conjugates across Solid Cancers
The Target Atlas for Antibody-Drug Conjugates across Solid Cancers
Abstract
Antibody-Drug Conjugates (ADCs) is a rapidly developing type of oncology therapeutic, spanning the targeted therapy for hematologic malignancies and solid cancers....
Abstract P5-12-08: Single-center experience in antibody drug conjugate sequencing in HER2-low metastatic breast cancer
Abstract P5-12-08: Single-center experience in antibody drug conjugate sequencing in HER2-low metastatic breast cancer
Abstract
Introduction: Two antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-Dxd) and sacituzumab govitecan (SG), were approved by the FDA for HER2 low and ...
The Highs, Lows, and Resurgence of Antibody-drug Conjugates
The Highs, Lows, and Resurgence of Antibody-drug Conjugates
Antibody-drug conjugates (ADCs) offer a way to deliver a cytotoxic or an immuno-stimulatory payload directly to tumors to maximize the anti-tumor efficacy of the payload with reduc...